FDA Approves New Anti-CGRP Injection for Adult Migraine Prevention

The FDA has approved fremanezumab-vfrm injection (Ajovy, Teva Pharmaceuticals) for the prevention of migraines in adults. Fremanezumab-vfrm is an antibody that blocks calcitonin gene–related peptide (CGRP) ligand from binding to receptors.